Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
Back

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Not Recruiting

Open to: FEMALE

Age: 18.0 - N/A

London Nottingham London London Northwood Sutton Taunton Manchester

Medical Conditions

Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Hypersensitivity

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Sep 2022 May 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called FRα. It is being developed for the treatment of participants with recurrent platinum-sensitive, high grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with FRα expression. FRα positivity will be defined by the Ventana FOLR1 Assay.

Intervention Arm Group : MIRV + Carboplatin;

Intervention Type : DRUG
Intervention Description : Carboplatin is considered to be the treatment agent of choice in relapsed PSOC.

Intervention Arm Group : MIRV + Carboplatin;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Hammersmith Hospital
    London
    W12 0HS
  • Nottingham University Hospitals NHS Trust
    Nottingham
    NG5 1PB
  • Guy's Hospital
    London
    SE1 9RT
  • The Royal Marsden NHS Foundation Trust
    London
    SW3 6JJ
  • Mount Vernon Cancer Centre
    Northwood
    HA6 2RN
  • The Royal Marsden NHS Foundation Trust
    Sutton
    Surrey
    SM2 5PT
  • Musgrove Park Hospital
    Taunton
    TA15DA
  • The Christie NUS Foundation Trust
    Manchester
    M20 4BX


The study is sponsored by AbbVie



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05456685
Last updated 29 January 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top